Tocilizumab and Covid-19 | NEJM

Audio Interview from the New England Journal of Medicine — Tocilizumab and Covid-19

Source: New England Journal of Medicine

Categories: Latest Headlines, Pulmonology

Tags: covid19

Tweets with this article

American Thoracic

RT @fritsfranssen: Lack of effect of anti-IL6 treatment in severe #COVID19. This might suggest that IL-6 is a consequence, rather than a driver of this disease. At least, there is no indication to prescribe this drug in severe COVID19 at this moment. https://t.co/wqu3sEa38u

Assembly Members to Unite in San Diego – ATSConferenceNews.org

The 14 Assemblies of the ATS will hold membership meetings in San Diego on Sunday, May 19, and Monday, May 20, during the International Conference.…

American Thoracic April 18, 2024

ATS 2024 International Conference

American Thoracic Society

American Thoracic April 18, 2024

ATS/ALAT Joint Webinar on Lung Infection – Dealing with MDR organisms in limited resources settings

Severe community-acquired pneumonia (SCAP) is a major concern worldwide as it is a leading cause of morbidity and mortality. The increasing incidence of mult…

American Thoracic April 16, 2024

Breathe Easy | Practical PH – PC Assembly Preview for ATS 2024

Drs. Khushboo Goel and Kathryn del Valle have a conversation with Drs. Stephen Chan and Andrea Frump, Pulmonary Circulation Assembly Programming Chairs for the ATS…

American Thoracic April 15, 2024

ATS 2024 International Conference

American Thoracic Society

American Thoracic April 15, 2024

Gregory Tino | Faculty | About Us | Perelman School of Medicine | Perelman School of Medicine at the University of Pennsylvania

We are the Perelman School of Medicine — the Nation’s First — and the Hospital of the University of Pennsylvania — the nation’s first hospital…

American Thoracic April 15, 2024

Related Articles